A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer
Metrics: PDF 1893 views | HTML 1802 views | ?
Dan-Zeng Ba-Sang1, Zi-Wen Long2,3, Hao Teng1, Xu-Peng Zhao1, Jian Qiu1, Ming-Shan Li1
1Department of Oncology, Shigatse People’s Hospital, Shigatse 857000, Tibet, P. R. China
2Department of Gastric Cancer and Soft-Tissue Sarcoma Surgery, Fudan university Shanghai Cancer Center, Shanghai 200032, P. R. China
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P. R. China
Zi-Wen Long, email: firstname.lastname@example.org
Keywords: colorectal cancer, targeted drug, chemotherapy, randomized controlled trial, network meta-analysis
Received: May 06, 2016 Accepted: October 02, 2016 Published: October 31, 2016
Objective: A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC).
Results: Twenty-seven RCTs were ultimately incorporated into this network meta-analysis. Compared with chemotherapy alone, bevacizumab + chemotherapy, panitumumab + chemotherapy and conatumumab + chemotherapy had higher PR rate. Bevacizumab + chemotherapy, cetuximab + chemotherapy, panitumumab + chemotherapy, trebananib + chemotherapy and conatumumab + chemotherapy had higher ORR rate in comparison to chemotherapy alone. Furthermore, bevacizumab + chemotherapy had higher DCR rate than chemotherapy alone. The results of our cluster analysis showed that chemotherapy combined with bevacizumab, cetuximab, panitumumab, conatumumab, ganitumab, or brivanib + cetuximab had better efficacies for the treatment of advanced/metastatic CRC in comparison to chemotherapy alone.
Materials and Methods: Electronic databases were comprehensively searched for potential and related randomized controlled trials (RCTs). Direct and indirect evidence were incorporated for evaluation of stable disease (SD), progressive disease (PD), complete response (CR), partial response (PR), disease control rate (DCR) and overall response ratio (ORR) by calculating odds ratio (OR) and 95% confidence intervals (CI), and using the surface under the cumulative ranking curve (SUCRA).
Conclusions: These results indicated that bevacizumab + chemotherapy, panitumumab + chemotherapy, conatumumab + chemotherapy and brivanib + cetuximab + chemotherapy may have better efficacies for the treatment of advanced/metastatic CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.